Abstract | OBJECTIVE: Large prospective studies have demonstrated that optimum glycemic control is not routinely achieved in clinical practice. Barriers to optimal insulin therapy include hypoglycemia, weight gain, and suboptimal initiation and dose titration. This study compared two treatment algorithms for insulin glargine initiation and titration: algorithm 1 (investigator led) versus algorithm 2 (performed by study subjects). RESEARCH DESIGN AND METHODS: A prospective, multicenter (n = 611), multinational (n = 59), open-label, 24-week randomized trial in 4,961 (algorithm 1, n = 2,493; algorithm 2, n = 2,468) suboptimally controlled type 2 diabetic subjects. RESULTS: At baseline, mean diabetes duration was 12.3 +/- 7.2 years, and 72% of subjects were pretreated with insulin. At end point, there was no significant difference in the incidence of severe hypoglycemia between algorithms 1 and 2 (0.9 vs. 1.1%). There was a significant reduction in HbA(1c) from 8.9 +/- 1.3 to 7.8 +/- 1.2%, with a greater decrease (P < 0.001) with algorithm 2 (-1.22%) versus algorithm 1 (-1.08%). Fasting blood glucose decreased from 170 to 110 mg/dl, with a greater decrease (P < 0.001) with algorithm 2 (-62 mg/dl) versus algorithm 1 (-57 mg/dl). Mean basal insulin dose increased from 22.9 +/- 15.5 to 43.0 +/- 25.5 IU, with a significant difference (P < 0.003) between algorithm 2 (21.6 IU) and algorithm 1 (18.7 IU). CONCLUSIONS:
|
Authors | Melanie Davies, Fred Storms, Simon Shutler, Monique Bianchi-Biscay, Ramon Gomis, ATLANTUS Study Group |
Journal | Diabetes care
(Diabetes Care)
Vol. 28
Issue 6
Pg. 1282-8
(Jun 2005)
ISSN: 0149-5992 [Print] United States |
PMID | 15920040
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Blood Glucose
- Hypoglycemic Agents
- Insulin
- Insulin, Long-Acting
- Insulin Glargine
|
Topics |
- Algorithms
- Blood Glucose
(drug effects, metabolism)
- Body Mass Index
- Diabetes Mellitus, Type 2
(blood, drug therapy)
- Female
- Humans
- Hypoglycemic Agents
(therapeutic use)
- Insulin
(analogs & derivatives, therapeutic use)
- Insulin Glargine
- Insulin, Long-Acting
- Male
- Middle Aged
- Patient Selection
- Safety
- Treatment Outcome
|